(Total Views: 236)
Posted On: 01/09/2020 3:42:35 PM
Post# of 1354
NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Announces Second Straight Year of Strong Publication Numbers of Scientific Papers Citing Advantages of its PCT Platform
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in 2019 – for the second straight year – over 20 scientific papers highlighting the advantages of PBI’s patented pressure cycling technology (“PCT”) platform were published worldwide. The publications, authored by independent scientists from academia, government, and industry, highlighted the powerful and enabling benefits of the PCT Platform in such critical areas as cancer research, food safety, and proteomics. “PCT-related scientific papers published in 2019 highlighted new and/or improved applications of the PCT Platform in a number of important and exciting areas of research, including cancer, food safety, and proteomics,” PBI’s Global Director of Sales and Marketing Roxana McCloskey said in the news release. “We are particularly pleased that several publications described protocols for combining the PCT Platform with existing technologies from other companies to fill a significant unmet need for high throughput protein processing of cancer biopsy tissues.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that in 2019 – for the second straight year – over 20 scientific papers highlighting the advantages of PBI’s patented pressure cycling technology (“PCT”) platform were published worldwide. The publications, authored by independent scientists from academia, government, and industry, highlighted the powerful and enabling benefits of the PCT Platform in such critical areas as cancer research, food safety, and proteomics. “PCT-related scientific papers published in 2019 highlighted new and/or improved applications of the PCT Platform in a number of important and exciting areas of research, including cancer, food safety, and proteomics,” PBI’s Global Director of Sales and Marketing Roxana McCloskey said in the news release. “We are particularly pleased that several publications described protocols for combining the PCT Platform with existing technologies from other companies to fill a significant unmet need for high throughput protein processing of cancer biopsy tissues.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
